The best news from Yemen on health and wellness
Provided by AGP
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
CAMBRIDGE, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, Erik Ostrowski, Chief Financial and Chief Business Officer, and Dr. Steven Burke, Chief Medical Officer, will participate in one-on-one meetings at the Raymond James 2026 Biotech Innovation Symposium on Tuesday, April 14 in New York, NY. Company presentations are not planned at the Symposium.
During meetings, management will discuss its commercial products, and data and other information shared during Akebia’s recent R&D Day that showcased its robust pipeline of clinical stage kidney disease programs.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
